| Cat.No. |
Product Name |
Information |
|
S8961
|
Alobresib (GS-5829) |
Alobresib (GS-5829) is a novel BET inhibitor that represents a highly effective therapeutics agent against recurrent/chemotherapy-resistant USC-overexpressing c-Myc. Alobresib (GS-5829) inhibits CLL cell proliferation and induces leukemia cell apoptosis through deregulation of key signaling pathways, such as BLK, AKT, ERK1/2, and MYC. Alobresib (GS-5829) also inhibits NF-κB signaling. |
|
S8785
|
A1874 |
A1874 is a much improved nutlin-based, BRD4-degrading PROTAC and is able to degrade its target protein by 98% with nanomolar potency. |
|
S6758
|
I-CBP112 |
I-CBP112 is a potent and selective CBP/p300 inhibitor with dissociation constant (KD) of 151 ± 6 nM and 167 ± 8 nM for CBP and p300, respectively. |
|
S8766
|
AT1 |
AT1 is highly selective Brd4 degrader which is a designed molecule based on the crystal structures of MZ1 bound to BRD4 as well as models of VHL proteins. |
|
S8574
|
BI 894999 |
BI894999 is a novel potent and selective BET inhibitor with IC50 values of 5 nM and 41 nM for the binding of BRD4-BD1 and BRD4-BD2 to acetylated histones, respectively. BI894999 is highly selective for BRD2/3/4 and BRDT (Kd of 0.49-1.6 nM), with at least a 200-fold selectivity vs. BRD4-BD1. |
| ≡ All Epigenetic Reader Domain Inhibitors |
